Response No-vote letter update, page-42

No, it was mentioned in the first study and not Data Confirmation. Bruh, if you are questioning the technology but it seem like you just invested for the COVID-19 screening and not ResAppDx since you seem to know very little about ResAppDx then it's time to sell or do more due diligence on ResAppDx which is RAP's core product.